Merck Gruppe

HSBC upgraded Merck KGaA from “hold” to “buy,” sending the stock up about 1.9% on Tuesday to €141.60. Analyst Rajesh Kumar cites valuation and notes that Merck had not fully participated in the recent sector rally. While growth in the life-science segment is likely to lag behind the first half of 2026 in the coming quarters, the fundamental growth drivers remain intact. From a chart perspective, the stock has broken above the 21- and 50-day moving averages, bringing the early July and August highs at just under €149 back into focus. » Plus sur de.investing.com

HSBC has raised Merck KGaA from “Hold” to “Buy” and names the company one of its favorites in the life‑science‑tools sector due to an attractive relative valuation. Analysts highlight strong growth in the first half of the year but note that the stock did not join the recent sector rally and that a slowdown in the second half is possible from inventory drawdown and controversial M&A mark‑ups. Despite these concerns, HSBC still expects structural growth, sees offset from an accelerating electronics segment, and views the expansion of cell‑therapy capacity positively over the long term; the share price rose about 1.7%. » Plus sur de.investing.com

Someone who bought €1,000 of Merck shares at the closing price of €166.00 three years ago would now have 6.024 shares in their portfolio. At a price of €140.25 on 28.08.2026 the investment is worth €844.88, a decline of 15.51%. All Merck shares most recently had a market value of €60.98 billion; stock splits and dividends were not taken into account in the calculation. » Plus sur finanzen.net